flow trial semaglutide all-cause mortality hazard ratio kidney outcomes 0.76 Chronic Kidney Disease flow trial semaglutide all-cause mortality

A fold-change (FC) 1.2 or FC 0.83 in the experimental group compared with that in the control group was considered as up- or downregulation of phospho-specific proteins

The ratio of urinary carnitine/acylcarnitine excretion of the patients and healthy controls could have helped us to understand better the altered carnitine-acylcarnitine homeostasis in these late-diagnosed congenital hypothyroid patients under treatment

In 2021, Johnson & Johnson agreed to settle existing Invokana lawsuits for an undisclosed amount

Vertigo and Dizziness in the Elderly

This leads to decreased hunger and increased satiety

Menopause and Sleep Apnea